What the studies show
Resting heart rate rises a few beats per minute, as with other glucagon-receptor agonists; long-term significance unknown.
Human trials exist and mostly agree, but there are too few of them, they are too small, or one big one is still reading out. Expect the grade to move.
- 1le Roux CW, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.Lancet Diabetes Endocrinol, 2024387 adults, 46 weeks.
In context
Survodutide is a once-weekly peptide that activates both the GLP-1 and glucagon receptors. In SYNCHRONIZE-1, a 725-person phase 3 trial published in June 2026, it produced 12–13% weight loss at 76 weeks against 5% on placebo, with gastrointestinal symptoms in up to 90% of participants. In people who also have type 2 diabetes the figure was 8–10% against 4% (SYNCHRONIZE-2, published October 2026). Its distinctive result is in the liver: a phase 2 trial resolved MASH without worsening fibrosis in 83% of patients at the top dose. It is not approved anywhere.
Survodutide is investigational. Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is Survodutide proven to cause heart rate increase?
What studies are behind the grade?
Is Survodutide approved for this?
Other outcomes for Survodutide
- BBody weight1 phase 3 RCT + phase 2
- BBody weight (obesity with type 2 diabetes)1 phase 3 RCT (n=752, 76 wk)
- BLiver disease (MASH resolution)1 phase 2 RCT; phase 3 running
- BLiver fat and visceral fatPhase 3 (SYNCHRONIZE-MASLD)
- BGI side effectsadversePhase 3
Written and maintained by LYO Research — how pages are written and checked. Reviewed 7 October 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →